MILLIMAN WHITE PAPER

Real-world claims analysis of menopause healthcare

Diagnosis, treatment, and comorbidities among commercially insured women, 2022 to 2024

Melanie K Kuester, PharmD, BCPS | Milliman
Theresa T Patton, PhD | TT Patton Consulting
Holly B Zeitvogel, MSHM | Milliman
Emma M Todd, MPH | Milliman

Milliman

Key findings

- Menopause appears to be underdiagnosed in a commercially insured population, with only about 25% of women ages 40 to 64 receiving a diagnosis.
- Primary care providers are central to menopause diagnosis and documentation.
- Treatment patterns are not fully aligned with diagnosis status, as some women receive therapy without a formal menopause diagnosis.
- Women with a menopause diagnosis have higher observed rates of selected comorbid conditions.
- Opportunities exist to improve recognition, align treatment pathways, and support better health outcomes for women in midlife.

Background

MENOPAUSE IS RECEIVING INCREASED PUBLIC AND CLINICAL ATTENTION

In the United States, approximately 1.3 million women enter menopause each year.[1] With increasing life expectancy, women may spend more than one-third of their lives in the postmenopausal stage.[2] Historically, menopause has been stigmatized and often not publicly discussed. This stigma intensified about 20 years ago when interpretations of data from the Women's Health Initiative raised concerns about hormone replacement therapy (HRT), and the U.S. Food and Drug Administration (FDA) subsequently added a boxed warning to HRT products.[3,4] In addition, many residency programs deprioritized menopause training, perpetuating limited communication by healthcare providers on the topic.[5] In the last few years, public conversation and awareness have shifted due to growing scientific knowledge, social and traditional media attention, increased passage of menopause-related legislation, and a rise in menopause healthcare spending.[6,7,8,9,10] Understanding how menopause is characterized, diagnosed, and treated in the U.S. healthcare system today is critical to supporting women's health in midlife and beyond.

MENOPAUSE IS A MAJOR BIOLOGICAL TRANSITION WITH A HIGH SYMPTOMATIC BURDEN

Menopause is a natural aspect of reproductive biology in women, defined clinically as the permanent end of menstruation after 12 consecutive months without a menstrual period (menses).[11] This reproductive transition typically occurs between the ages of 45 and 55 and reflects declining estrogen production and cessation of ovarian follicular activity.[12]

Prior to menopause, women often experience a transitional phase known as perimenopause, which may persist for years.[13] Perimenopause is characterized by hormonal fluctuations, irregular menstrual cycles, and other symptoms associated with declining estrogen levels.[14] Vasomotor symptoms, including hot flashes and night sweats, are among the most reported and affect up to 80% of perimenopausal women.[15] Other frequently reported symptoms include sleep disturbances, fatigue, mood changes, vaginal dryness, decreased libido, and cognitive complaints.[16] In general, menopause is associated with physiological changes that may influence long-term health, metabolism, bone density, and vascular function.[17] These symptoms may also extend into the postmenopausal phase.[18]

Clinical guidelines from organizations such as The Menopause Society (formerly the North American Menopause Society) outline various therapeutic options for the management of menopausal symptoms.[19] According to its 2022 position statement, HRT remains the most effective treatment for vasomotor symptoms and other menopause-related complaints in appropriate patients.[20] Nonhormonal pharmacologic therapies—including neurokinin 3 receptor antagonists, certain antidepressants, anticonvulsants, and other medications—may be used when HRT is contraindicated or not preferred.[21]

PERIMENOPAUSE/MENOPAUSE IS CLINICALLY UNDERRECOGNIZED AND UNDERTREATED

Perimenopause has received comparatively limited attention in clinical care and research relative to other chronic conditions affecting women.[22] Many current diagnosis codes for menopause do not distinguish between the two ends of the menopause spectrum: perimenopause and postmenopause. Code definitions include guidance to be used for both states. Limited awareness of many menopausal symptoms can lead to underreporting by patients and lack of attribution to a menopausal state by providers because of gaps in medical education.[23] Thus, menopausal states frequently go underrecognized by providers and undiagnosed. Specific menopausal symptoms may be managed individually rather than under a broader context of the menopausal transition.

HRT is a longstanding treatment for perimenopausal and postmenopausal symptoms and remains the standard of care today for most women.[24] After decades of research, the FDA removed the broad boxed warnings for HRT products in November 2025.[25] However, the changes in general medical understanding of when HRT may be appropriate have not yet become a standard part of training and practice, and many patients and providers remain hesitant about its use.[26,27,28] Thus, many women's symptoms may be undertreated with HRT.

REAL-WORLD CLAIMS DATA ANALYSIS IS NEEDED FOR MENOPAUSAL DIAGNOSIS, TREATMENT, AND COMORBIDITIES

Relatively little research has examined how menopause is diagnosed and managed in routine clinical practice using large-scale, real-world healthcare data.[29] In particular, there is limited evidence for how a formal menopause diagnosis relates to broader patterns of comorbid diagnoses and pharmacological treatment in women during midlife.[30] Understanding the relationships among symptoms, diagnosis, and treatment is critical, as menopause may represent a clinical inflection point during which multiple symptoms and health conditions emerge but are not consistently attributed to a common underlying cause.[31]

In this study, we investigated real-world evidence for menopausal diagnosis, treatment, and comorbidities among midlife women. Using a commercial claims database, we examined whether pharmacologic treatment aligned with diagnosis status and if HRT or a non-HRT alternative was used in treatment. We also compared comorbidity patterns between women both with and without a clinical menopause diagnosis and those who had received treatment or not.

Methodology

We performed an observational, retrospective claims analysis using the group commercial dataset within the Milliman Consolidated Healthcare Cost Guidelines™ Sources Database (CHSD) for calendar years 2022 to 2024. The dataset includes enrollment and closed medical and pharmacy claim files for employer-sponsored, group commercial enrollment of more than 44 million lives.

Women were included in the analysis if they were 40 to 64 years old at the beginning of the study period and had 36 months of continuous commercial insurance enrollment. Since most menopausal-state diagnosis codes do not distinguish a perimenopausal from a postmenopausal state, this study did not distinguish among menopausal stages. To be included in the diagnosed cohort, women had to have at least one of the following International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes on a nonlaboratory or nonradiology claim during the study period: E28.310, E28.319, E89.40, E89.41, N95.x, or Z78.0. If none of the 10 identifying codes were present, women were placed into the undiagnosed cohort. Appendix Figure A contains a list of the menopausal-state diagnosis codes and descriptions.

Women also were grouped into two treatment cohorts: treatment of menopausal state or no treatment. These cohorts are independent from the diagnosis cohorts. Thus, individuals could be treated with a menopause therapy but not have a menopause diagnosis. Treatment was defined as either HRT or non-HRT therapy, which included prescription therapies that received a Level I, II, or III recommendation for use in menopause by The Menopause Society in its 2023 nonhormone therapy position statement (i.e., selective serotonin reuptake inhibitors, gabapentinoids, neurokinin B antagonists, and oxybutynin).[32] Treatment groups were non-exclusive, meaning an individual could be present in both treatment groups. Figure 1 displays the patient counts of each cohort beginning with the entire female population within the data.

FIGURE 1: PATIENT COHORTS



Prevalence of menopause-related comorbidities such as cardiovascular, metabolic, mood, sleep, and other physiological disturbances were assessed in each cohort. A complete list of ICD-10-CM comorbidity codes included for analysis can be found in Appendix Figure B.

Results by diagnosis and treatment cohorts are reported in five-year age bands (i.e., 40 to 44; 45 to 49; 50 to 54; 55 to 59; 60 to 64 years) for all but the comorbidity occurrence, which is reported for the entire age group. Descriptive statistics were reported for each primary cohort. Chi-square tests were used for each crosswise comparison to evaluate statistical significance for comorbidity prevalence between cohorts. A p-value of less than 0.05 was deemed statistically significant.

Results and discussion

Our findings appear to consistently support four core themes:

1. Menopause underdiagnosis
2. Primary care support for menopause
3. Diagnosis–treatment misalignment
4. Comorbidity burden with menopause diagnosis

We consider each theme in turn below.

1. MENOPAUSE UNDERDIAGNOSIS

Nearly 23 million women were identified in the data. Of those, 2,068,340 were ages 40 to 64 years and were enrolled for 36 months. Among these women, 515,855, or approximately 25%, were observed to have a diagnosis of a menopausal state, either symptomatic or asymptomatic. Of these, 309,549 women, or approximately 15% of enrolled women, received an incident menopause diagnosis after having no diagnoses observed in the first 12 months of the study period.

Figure 2 shows the distribution of menopause diagnosis by age band. The highest prevalence of diagnosis was women ages 50 to 54 years (34.2%). The lowest was women ages 40 to 44 (10.1%). Appendix Figure C contains complete diagnosis prevalence across age cohorts.

FIGURE 2: PERCENTAGE OF WOMEN WITH OBSERVED DIAGNOSIS FOR A MENOPAUSAL STATE IN A COMMERCIAL POPULATION, 2022–2024



The incidence of first-time menopause diagnoses followed a similar pattern as overall diagnoses by age, peaking among women ages 50 to 54 years (Figure 3). Nonetheless, fewer than 20% of women in any age group received a new menopause diagnosis. These findings highlight the broader issue that menopause may be underdiagnosed or inconsistently recorded, even during the age range when diagnosis is most likely.

FIGURE 3: PREVALENCE OF WOMEN WITH OBSERVED INCIDENT DIAGNOSIS FOR A MENOPAUSAL STATE IN A COMMERCIAL POPULATION, 2022–2024



Key takeaways: The prevalence of menopause diagnosis increased with age, peaking at ages 50 to 54, in line with the typical menopausal transition. However, the overall diagnosis rate across cohorts (24.9%) was much lower than expected for such a nearly universal biological transition. Even among women in this study group—who had consistent insurance coverage and regular healthcare visits—fewer than one in three received a menopause diagnosis. Because diagnosis codes for menopausal states do not distinguish between perimenopause and postmenopause, and because both symptomatic and asymptomatic codes were included in this study, one of the diagnosis codes could reasonably be expected for many women in the study population. The observed low diagnosis rate indicates potential broad under-recognition or inconsistent documentation in clinical settings.

Implications: Perimenopause lasts on average 7 to 10 years, and the postmenopausal state is permanent. As research on the timing of menopause treatment continues to emerge regarding the potential impact on other conditions such as cardiovascular disease and Alzheimer's disease, timely diagnosis of a menopausal state is key for women's overall healthcare in midlife and beyond.[33,34,35,36]

2. PRIMARY CARE SUPPORT FOR MENOPAUSE

Regardless of menopause diagnosis, women had approximately a 10 to 1 ratio of primary care to gynecology visits when measured on a per-member-per-year basis (Figure 4). Among women in the incident menopause cohort, twice as many women received the diagnosis from a primary care provider (PCP) as from a gynecologist (Gyn). Figure 5 shows that fewer than 1 in 5 women were diagnosed by a healthcare provider other than a PCP or Gyn.

FIGURE 4: AVERAGE NUMBER OF VISITS FOR WOMEN AGES 40 TO 64 SHOWN ON A PER-MEMBER-PER-YEAR BASIS

	MENOPAUSE COHORT		NO MENOPAUSE COHORT	
AGE BAND	PCP IN-PERSON VISITS	GYN IN-PERSON VISITS	PCP IN-PERSON VISITS	GYN IN-PERSON VISITS
40–44	3.1	0.4	1.9	0.2
45–49	3.0	0.3	2.0	0.1
50–54	2.9	0.3	2.1	0.1
55–59	3.0	0.2	2.2	0.0
60–64	3.1	0.2	2.3	0.0
Overall	3.0	0.3	2.1	0.1

FIGURE 5: PERCENT OF MEMBERS WITH INCIDENT MENOPAUSE DIAGNOSED BY PROVIDER TYPE IN THE COMMERCIAL POPULATION



Key takeaways: Across age bands, women had substantially more primary care visits than gynecology visits, with an overall average of 3.0 PCP visits per member per year compared with 0.3 Gyn visits in the menopause cohort and 2.1 versus 0.1 visits, respectively, in the no-menopause cohort. This suggests that PCPs have more frequent opportunities to identify menopausal symptoms, connect them to the menopausal transition, and document a diagnosis. Among women with an incident menopause diagnosis, PCPs were more likely than Gyns to be the first clinician to add a menopause diagnosis code. Among women with an incident menopause diagnosis, PCPs diagnosed more than half of the cohort.

Implications: PCPs appear to play a central role in menopause recognition and documentation. Even though gynecology remains an important source of specialty care, the frequency with which women see their PCPs demonstrates that these providers have the greatest ability to make a difference in narrowing the diagnosis gap.

3. DIAGNOSIS–TREATMENT MISALIGNMENT

Although diagnosis patterns suggest menopause might be overlooked in everyday clinical practice, treatment patterns also show fragmentation between symptom management and formal menopause diagnosis. Figure 6 shows the proportion of women who received treatment for menopausal symptoms in the diagnosed and undiagnosed cohorts along with the type of treatment received (HRT vs. non-HRT). The overall treatment percentage was 25.8%, with most women receiving HRT (25.5%). The treatment percentage was slightly higher for women in their 50s versus other age bands. Interestingly, an average of 4% of women (n=61,960) received HRT but did not have a diagnosis of menopause. This value peaked around 5% for women in their 50s.

FIGURE 6: PERCENTAGE OF WOMEN RECEIVING THERAPIES THAT MAY BE USED FOR MENOPAUSAL SYMPTOMS IN A COMMERCIAL POPULATION, 2022–2024

AGE BAND (YEARS)	MEMBERS DIAGNOSED WITH MENOPAUSE RECEIVING THERAPIES		
	HRT n (%)	NON-HRT n (%)	EITHER CATEGORY OF TREATMENT n (%)
40–44	7,202 (17.8%)	120 (0.3%)	7,281 (18.0%)
45–49	20,594 (21.6%)	407 (0.4%)	20,840 (21.9%)
50–54	41,209 (26.8%)	891 (0.6%)	41,677 (27.1%)
55–59	38,560 (29.0%)	885 (0.7%)	38,996 (29.4%)
60–64	24,008 (25.6%)	693 (0.7%)	24,380 (26.0%)
Overall	131,573 (25.5%)	2,996 (0.6%)	133,174 (25.8%)

AGE BAND (YEARS)	MEMBERS NOT DIAGNOSED WITH MENOPAUSE RECEIVING THERAPIES		
	HRT n (%)	NON-HRT n (%)	EITHER CATEGORY OF TREATMENT n (%)
40–44	7,070 (2.0%)	54 (0.0%)	7,111 (2.0%)
45–49	8,990 (2.9%)	127 (0.0%)	9,093 (3.0%)
50–54	15,073 (5.1%)	295 (0.1%)	15,298 (5.2%)
55–59	17,936 (5.5%)	576 (0.2%)	18,387 (5.6%)
60–64	12,891 (4.9%)	629 (0.2%)	13,402 (5.1%)
Overall	61,960 (4.0%)	1,681 (0.1%)	63,291 (4.1%)

Key takeaways: Treatment use was higher among women with a documented menopause diagnosis compared with those without, indicating that diagnosis might be key in treatment recognition and initiation. However, only about 25% of diagnosed women received menopause-related therapy (namely HRT), and a smaller, yet meaningful, portion of women without a documented diagnosis also received treatment.

Implications: Treatment patterns reveal a lack of consistent menopause management. Although not every woman in a menopausal state may need pharmacological treatment, the inconsistency suggests 1) incomplete documentation of medical conditions when prescribing medications as seen by claims for symptom-driven treatment existing outside of a formal diagnosis; and 2) potential care gaps, characterized by possible undertreatment in diagnosed, symptomatic women. Consequently, menopause may not be consistently identified as the root cause of symptoms, hampering comprehensive management.

Also, a provider may code a menopausal state but not identify themselves as the primary provider to treat those symptoms. Thus, due to care gaps across multiple providers and healthcare networks, women may go untreated, underscoring a lack of integration in menopause care.

4. COMORBIDITY BURDEN WITH MENOPAUSE DIAGNOSIS

This study also assessed the prevalence of 15 frequently associated comorbidities[37] across the diagnosed and treated cohorts. Findings suggest that recognition of menopause may influence broader patterns of clinical evaluation and identification of health conditions during midlife. In our analysis, women with a menopause diagnosis, regardless of treatment status, had higher rates of diagnosis for all comorbidities evaluated than those without a menopause diagnosis (Figure 7). Hyperlipidemia had the largest difference in diagnosis rates (34.7% vs. 26.8%, respectively). Anxiety and fatigue also had large absolute differences in diagnosis (31.1% vs. 22.8% and 17.1% vs. 8.5%, respectively). Conversely, cardiovascular disease and thrombosis (defined as a deep venous thrombosis [DVT] or pulmonary embolism [PE]) were found to have the smallest differences (0.9% vs. 0.8% and 1.4% vs. 1.2%, respectively).

In the treated cohort, women who were diagnosed and received treatment had an 82.2% prevalence of any examined comorbidity, compared with 71.1% among women who were treated but lacked a diagnosis (Figure 7). This pattern of increased prevalence persisted across most comorbidities, with the exceptions of hypertension and cardiovascular disease; the diagnosed and treated populations for these diseases were lower than the treated population without a diagnosis (31.2% and 3.4% vs. 32.2% and 3.5%, respectively), and hypertension was lower than the average for all women in the non-diagnosed cohort (31.2% vs. 32.1%).

FIGURE 7: PERCENTAGE OF WOMEN WITH SELECTED COMORBIDITIES BASED ON MENOPAUSE DIAGNOSIS IN A COMMERCIAL POPULATION, 2022–2024

COMORBIDITIES	MENOPAUSE DIAGNOSIS n (%)	NO MENOPAUSE DIAGNOSIS n (%)	P-VALUE	MENOPAUSE DIAGNOSIS + ANY TREATMENT n (%)	NO MENOPAUSE DIAGNOSIS + ANY TREATMENT n (%)	P-VALUE
Any comorbidity	417,073 (80.9%)	997,864 (64.3%)	<0.001	109,484 (82.2%)	44,983 (71.1%)	<0.001
Hypertension	179,775 (34.8%)	498,113 (32.1%)	<0.001	41,585 (31.2%)	20,382 (32.2%)	<0.001
Anxiety	160,504 (31.1%)	353,967 (22.8%)	<0.001	45,359 (34.1%)	17,954 (28.4%)	<0.001
Hyperlipidemia	178,817 (34.7%)	416,182 (26.8%)	<0.001	45,065 (33.8%)	19,434 (30.7%)	<0.001
Depression	116,903 (22.7%)	257,401 (16.6%)	<0.001	32,837 (24.7%)	13,235 (20.9%)	<0.001
Obesity	115,404 (22.4%)	285,352 (18.4%)	<0.001	26,358 (19.8%)	11,358 (17.9%)	<0.001
Fatigue	88,215 (17.1%)	131,555 (8.5%)	<0.001	23,832 (17.9%)	7,261 (11.5%)	<0.001
Sleep disturbances	57,900 (11.2%)	88,789 (5.7%)	<0.001	17,840 (13.4%)	5,638 (8.9%)	<0.001
Hypercholesterolemia	47,843 (9.3%)	99,761 (6.4%)	<0.001	12,440 (9.3%)	4,950 (7.8%)	<0.001
Atrophic vaginitis	38,739 (7.5%)	277 (0.0%)	<0.001	19,698 (15.0%)	119 (0.2%)	<0.001
Osteoporosis	23,333 (4.5%)	32,590 (2.1%)	<0.001	7,057 (3%)	2,726 (4.3%)	<0.001
Cardiovascular disease	18,203 (3.5%)	45,587 (2.9%)	<0.001	4,594 (3.4%)	2,207 (3.5%)	0.68
Metabolic syndrome	10,811 (2.1%)	19,740 (1.3%)	<0.001	2,709 (2.0%)	935 (1.5%)	<0.001
DVT/PE	7,099 (1.4%)	18,329 (1.2%)	<0.001	1,457 (1.1%)	657 (1.0%)	0.27
Hyperhidrosis	5,692 (1.1%)	6,132 (0.4%)	<0.001	1,752 (1.3%)	431 (0.7%)	<0.001
Cerebrovascular disease	4,548 (0.9%)	11,685 (0.8%)	<0.001	1,029 (0.8%)	444 (0.7%)	0.09

Key takeaways: These findings suggest that a menopause diagnosis may be associated with greater clinical recognition, evaluation, and documentation of related health conditions. Women diagnosed with menopause consistently showed statistically significantly higher rates of comorbid conditions ($p<0.05$) across nearly all examined categories. The largest absolute differences were in conditions related to midlife hormonal changes, such as hyperlipidemia, anxiety, fatigue, and sleep issues. The diagnosed and treated population also generally experienced a statistically significant increase in diagnosed comorbidities with a few exceptions. It is notable that the diagnosed and treated population experienced lower rates of comorbid hypertension than their counterparts.

Implications: Because all women in the study were in the same midlife age range and likely experiencing similar biological transitions, the higher observed comorbidity rates may reflect differences in clinical engagement or diagnostic attention rather than differences in underlying disease burden alone. A documented menopause diagnosis may therefore serve as an important trigger for broader assessment and management of midlife health concerns. Additional longitudinal research on claims data and patient-identified outcomes is needed to determine whether women without documented menopause diagnoses are at greater risk for delayed identification, worsening symptoms, or progression of related conditions.

Conclusions

Overall, our real-world claims analysis reveals significant gaps in how menopause is recognized, diagnosed, and managed in commercially insured women during midlife. It is consistent with a 2023 Milliman report where 21% of women in the commercially insured population between the ages of 45 and 54 were found to have a menopause diagnosis or claim for menopause treatment in 2021.[38] Taken together, this study may show a slight increase in recognition and diagnosis in the following years. However, the results indicate that menopause is still not consistently identified in routine clinical care, even among women who are regularly engaged with healthcare services.

What does menopause underdiagnosis mean for healthcare industry stakeholders?

Healthcare professionals

Healthcare professionals can improve midlife care by recognizing menopause as a unifying clinical condition, documenting it consistently, and linking symptom management to coordinated assessment and treatment pathways.

Life sciences manufacturers

The diagnosis gap highlights an opportunity to support awareness, education, and diagnostic accuracy so patients are appropriately identified and connected to treatment as options evolve.

Payers and employers

Menopause recognition can become an opportunity to support earlier identification, coordinated care, and proactive management of symptoms and related comorbidities that may affect costs, productivity, and long-term health outcomes.

The misalignment among diagnosis, treatment, and comorbidity patterns highlights an opportunity for more cohesive menopause care approaches that view menopause as a comprehensive health transition rather than a collection of separate, unconnected symptoms. Better recognition and management could enable earlier intervention, foster more coordinated care, and potentially lead to improved long-term health outcomes for women in midlife and beyond.

Caveats and limitations

This study was an observational, retrospective claims analysis and therefore has several limitations common to analyses using administrative healthcare data. Findings depend on the accuracy, completeness, and consistency of diagnosis, procedure, provider, and pharmacy coding. Conditions that were not coded on a claim or inconsistently coded may not have been captured.

The dataset is strictly insurance claims data and not data from electronic medical records or cash-based systems. Thus, symptom severity, menopause stage, duration of symptoms, over-the-counter (OTC) medication use, lifestyle factors, or patient-reported outcomes were not captured. Provider and pharmacy organizations providing cash-only services for care, compounded bioidentical hormones, or other treatments were not captured as part of this analysis.

Race and ethnicity data are not captured in the dataset. However, there are known differences in average perimenopause length, treatment rate, and diagnosis rate across racial and ethnic groups.[39,40] The study data could not be used to identify those differences.

This study was designed to analyze women with consistent health insurance coverage; results may differ for women with Medicaid, who are uninsured, have intermittent coverage, or whose coverage changes over time. Underdiagnosis is likely present across populations, but comorbidity patterns and rates of menopause underdiagnosis may vary.

This independent research publication is intended to provide general information on trends in menopause-related healthcare and should not be construed as medical, financial, or actuarial advice applicable to any specific individual or organization. Readers should consult qualified professionals before making decisions based on the information presented here.

Appendix

APPENDIX FIGURE A: ALL MENOPAUSAL-STATE DIAGNOSIS CODES

DIAGNOSIS CODE	DESCRIPTION
E28.310	Symptomatic premature menopause
E28.319	Asymptomatic premature menopause
E89.40	Asymptomatic postprocedural ovarian failure
E89.41	Symptomatic postprocedural ovarian failure
N95.0	Postmenopausal bleeding
N95.1	Menopausal and female climacteric states
N95.2	Postmenopausal atrophic vaginitis
N95.8	Other specified menopausal and perimenopausal disorders
N95.9	Unspecified menopausal and perimenopausal disorder
Z78.0	Asymptomatic menopausal state

APPENDIX FIGURE B: COMORBIDITY CONDITIONS AND DIAGNOSIS CODES

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Sleep disturbances	F5112	Insufficient sleep syndrome
Sleep disturbances	F519	Sleep disorder not due to a substance or known physiological condition, unspecified
Sleep disturbances	G478	Other sleep disorders
Sleep disturbances	G479	Sleep disorder, unspecified
Sleep disturbances	F5101	Primary insomnia
Sleep disturbances	F5102	Adjustment insomnia
Sleep disturbances	F5105	Insomnia due to other mental disorder
Sleep disturbances	F5109	Other insomnia not due to a substance or known physiological condition
Sleep disturbances	G4700	Insomnia, unspecified
Sleep disturbances	G4701	Insomnia due to medical condition
Sleep disturbances	G4709	Other insomnia
Fatigue	G9332	Myalgic encephalomyelitis/chronic fatigue syndrome
Fatigue	R5383	Other fatigue
Fatigue	R5382	Chronic fatigue, unspecified
Anxiety	F411	Generalized anxiety disorder
Anxiety	F413	Other mixed anxiety disorders
Anxiety	F418	Other specified anxiety disorders
Anxiety	F419	Anxiety disorder, unspecified
Anxiety	F4322	Adjustment disorder with anxiety
Anxiety	F4323	Adjustment disorder with mixed anxiety and depressed mood
Depression	F32A	Depression, unspecified
Depression	Z1331	Encounter for screening for depression

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Depression	F0631	Mood disorder due to known physiological condition with depressive features
Depression	F0632	Mood disorder due to known physiological condition with major depressive-like episode
Depression	F328	Other depressive episodes
Depression	F3289	Other specified depressive episodes
Depression	F329	Major depressive disorder, single episode, unspecified
Depression	F330	Major depressive disorder, recurrent, mild
Depression	F331	Major depressive disorder, recurrent, moderate
Depression	F332	Major depressive disorder, recurrent severe without psychotic features
Depression	F333	Major depressive disorder, recurrent, severe with psychotic symptoms
Depression	F3340	Major depressive disorder, recurrent, in remission, unspecified
Depression	F3341	Major depressive disorder, recurrent, in partial remission
Depression	F3342	Major depressive disorder, recurrent, in full remission
Depression	F338	Other recurrent depressive disorders
Depression	F339	Major depressive disorder, recurrent, unspecified
Osteoporosis	M8000XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture
Osteoporosis	M8000XD	Age-related osteoporosis with current pathological fracture, unspecified site, subsequent encounter for fracture with routine healing
Osteoporosis	M8000XG	Age-related osteoporosis with current pathological fracture, unspecified site, subsequent encounter for fracture with delayed healing
Osteoporosis	M8000XK	Age-related osteoporosis with current pathological fracture, unspecified site, subsequent encounter for fracture with nonunion
Osteoporosis	M8000XP	Age-related osteoporosis with current pathological fracture, unspecified site, subsequent encounter for fracture with malunion
Osteoporosis	M8000XS	Age-related osteoporosis with current pathological fracture, unspecified site, sequela
Osteoporosis	M80011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture
Osteoporosis	M80011D	Age-related osteoporosis with current pathological fracture, right shoulder, subsequent encounter for fracture with routine healing
Osteoporosis	M80011G	Age-related osteoporosis with current pathological fracture, right shoulder, subsequent encounter for fracture with delayed healing
Osteoporosis	M80011K	Age-related osteoporosis with current pathological fracture, right shoulder, subsequent encounter for fracture with nonunion
Osteoporosis	M80011P	Age-related osteoporosis with current pathological fracture, right shoulder, subsequent encounter for fracture with malunion
Osteoporosis	M80011S	Age-related osteoporosis with current pathological fracture, right shoulder, sequela
Osteoporosis	M80012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture
Osteoporosis	M80012D	Age-related osteoporosis with current pathological fracture, left shoulder, subsequent encounter for fracture with routine healing
Osteoporosis	M80012G	Age-related osteoporosis with current pathological fracture, left shoulder, subsequent encounter for fracture with delayed healing
Osteoporosis	M80012K	Age-related osteoporosis with current pathological fracture, left shoulder, subsequent encounter for fracture with nonunion
Osteoporosis	M80012P	Age-related osteoporosis with current pathological fracture, left shoulder, subsequent encounter for fracture with malunion
Osteoporosis	M80012S	Age-related osteoporosis with current pathological fracture, left shoulder, sequela

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Osteoporosis	M80019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture
Osteoporosis	M80019D	Age-related osteoporosis with current pathological fracture, unspecified shoulder, subsequent encounter for fracture with routine healing
Osteoporosis	M80019G	Age-related osteoporosis with current pathological fracture, unspecified shoulder, subsequent encounter for fracture with delayed healing
Osteoporosis	M80019K	Age-related osteoporosis with current pathological fracture, unspecified shoulder, subsequent encounter for fracture with nonunion
Osteoporosis	M80019P	Age-related osteoporosis with current pathological fracture, unspecified shoulder, subsequent encounter for fracture with malunion
Osteoporosis	M80019S	Age-related osteoporosis with current pathological fracture, unspecified shoulder, sequela
Osteoporosis	M80021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture
Osteoporosis	M80021D	Age-related osteoporosis with current pathological fracture, right humerus, subsequent encounter for fracture with routine healing
Osteoporosis	M80021G	Age-related osteoporosis with current pathological fracture, right humerus, subsequent encounter for fracture with delayed healing
Osteoporosis	M80021K	Age-related osteoporosis with current pathological fracture, right humerus, subsequent encounter for fracture with nonunion
Osteoporosis	M80021P	Age-related osteoporosis with current pathological fracture, right humerus, subsequent encounter for fracture with malunion
Osteoporosis	M80021S	Age-related osteoporosis with current pathological fracture, right humerus, sequela
Osteoporosis	M80022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture
Osteoporosis	M80022D	Age-related osteoporosis with current pathological fracture, left humerus, subsequent encounter for fracture with routine healing
Osteoporosis	M80022G	Age-related osteoporosis with current pathological fracture, left humerus, subsequent encounter for fracture with delayed healing
Osteoporosis	M80022K	Age-related osteoporosis with current pathological fracture, left humerus, subsequent encounter for fracture with nonunion
Osteoporosis	M80022P	Age-related osteoporosis with current pathological fracture, left humerus, subsequent encounter for fracture with malunion
Osteoporosis	M80022S	Age-related osteoporosis with current pathological fracture, left humerus, sequela
Osteoporosis	M80029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture
Osteoporosis	M80029D	Age-related osteoporosis with current pathological fracture, unspecified humerus, subsequent encounter for fracture with routine healing
Osteoporosis	M80029G	Age-related osteoporosis with current pathological fracture, unspecified humerus, subsequent encounter for fracture with delayed healing
Osteoporosis	M80029K	Age-related osteoporosis with current pathological fracture, unspecified humerus, subsequent encounter for fracture with nonunion
Osteoporosis	M80029P	Age-related osteoporosis with current pathological fracture, unspecified humerus, subsequent encounter for fracture with malunion
Osteoporosis	M80029S	Age-related osteoporosis with current pathological fracture, unspecified humerus, sequela
Osteoporosis	M80031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture
Osteoporosis	M80031D	Age-related osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with routine healing
Osteoporosis	M80031G	Age-related osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with delayed healing

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Osteoporosis	M80031K	Age-related osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with nonunion
Osteoporosis	M80031P	Age-related osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with malunion
Osteoporosis	M80031S	Age-related osteoporosis with current pathological fracture, right forearm, sequela
Osteoporosis	M80032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture
Osteoporosis	M80032D	Age-related osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with routine healing
Osteoporosis	M80032G	Age-related osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with delayed healing
Osteoporosis	M80032K	Age-related osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with nonunion
Osteoporosis	M80032P	Age-related osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with malunion
Osteoporosis	M80032S	Age-related osteoporosis with current pathological fracture, left forearm, sequela
Osteoporosis	M80039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture
Osteoporosis	M80039D	Age-related osteoporosis with current pathological fracture, unspecified forearm, subsequent encounter for fracture with routine healing
Osteoporosis	M80039G	Age-related osteoporosis with current pathological fracture, unspecified forearm, subsequent encounter for fracture with delayed healing
Osteoporosis	M80039K	Age-related osteoporosis with current pathological fracture, unspecified forearm, subsequent encounter for fracture with nonunion
Osteoporosis	M80039P	Age-related osteoporosis with current pathological fracture, unspecified forearm, subsequent encounter for fracture with malunion
Osteoporosis	M80039S	Age-related osteoporosis with current pathological fracture, unspecified forearm, sequela
Osteoporosis	M80041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture
Osteoporosis	M80041D	Age-related osteoporosis with current pathological fracture, right hand, subsequent encounter for fracture with routine healing
Osteoporosis	M80041G	Age-related osteoporosis with current pathological fracture, right hand, subsequent encounter for fracture with delayed healing
Osteoporosis	M80041K	Age-related osteoporosis with current pathological fracture, right hand, subsequent encounter for fracture with nonunion
Osteoporosis	M80041P	Age-related osteoporosis with current pathological fracture, right hand, subsequent encounter for fracture with malunion
Osteoporosis	M80041S	Age-related osteoporosis with current pathological fracture, right hand, sequela
Osteoporosis	M80042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture
Osteoporosis	M80042D	Age-related osteoporosis with current pathological fracture, left hand, subsequent encounter for fracture with routine healing
Osteoporosis	M80042G	Age-related osteoporosis with current pathological fracture, left hand, subsequent encounter for fracture with delayed healing
Osteoporosis	M80042K	Age-related osteoporosis with current pathological fracture, left hand, subsequent encounter for fracture with nonunion
Osteoporosis	M80042P	Age-related osteoporosis with current pathological fracture, left hand, subsequent encounter for fracture with malunion
Osteoporosis	M80042S	Age-related osteoporosis with current pathological fracture, left hand, sequela
Osteoporosis	M80049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Osteoporosis	M80049D	Age-related osteoporosis with current pathological fracture, unspecified hand, subsequent encounter for fracture with routine healing
Osteoporosis	M80049G	Age-related osteoporosis with current pathological fracture, unspecified hand, subsequent encounter for fracture with delayed healing
Osteoporosis	M80049K	Age-related osteoporosis with current pathological fracture, unspecified hand, subsequent encounter for fracture with nonunion
Osteoporosis	M80049P	Age-related osteoporosis with current pathological fracture, unspecified hand, subsequent encounter for fracture with malunion
Osteoporosis	M80049S	Age-related osteoporosis with current pathological fracture, unspecified hand, sequela
Osteoporosis	M80051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture
Osteoporosis	M80051D	Age-related osteoporosis with current pathological fracture, right femur, subsequent encounter for fracture with routine healing
Osteoporosis	M80051G	Age-related osteoporosis with current pathological fracture, right femur, subsequent encounter for fracture with delayed healing
Osteoporosis	M80051K	Age-related osteoporosis with current pathological fracture, right femur, subsequent encounter for fracture with nonunion
Osteoporosis	M80051P	Age-related osteoporosis with current pathological fracture, right femur, subsequent encounter for fracture with malunion
Osteoporosis	M80051S	Age-related osteoporosis with current pathological fracture, right femur, sequela
Osteoporosis	M80052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture
Osteoporosis	M80052D	Age-related osteoporosis with current pathological fracture, left femur, subsequent encounter for fracture with routine healing
Osteoporosis	M80052G	Age-related osteoporosis with current pathological fracture, left femur, subsequent encounter for fracture with delayed healing
Osteoporosis	M80052K	Age-related osteoporosis with current pathological fracture, left femur, subsequent encounter for fracture with nonunion
Osteoporosis	M80052P	Age-related osteoporosis with current pathological fracture, left femur, subsequent encounter for fracture with malunion
Osteoporosis	M80052S	Age-related osteoporosis with current pathological fracture, left femur, sequela
Osteoporosis	M80059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture
Osteoporosis	M80059D	Age-related osteoporosis with current pathological fracture, unspecified femur, subsequent encounter for fracture with routine healing
Osteoporosis	M80059G	Age-related osteoporosis with current pathological fracture, unspecified femur, subsequent encounter for fracture with delayed healing
Osteoporosis	M80059K	Age-related osteoporosis with current pathological fracture, unspecified femur, subsequent encounter for fracture with nonunion
Osteoporosis	M80059P	Age-related osteoporosis with current pathological fracture, unspecified femur, subsequent encounter for fracture with malunion
Osteoporosis	M80059S	Age-related osteoporosis with current pathological fracture, unspecified femur, sequela
Osteoporosis	M80061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture
Osteoporosis	M80061D	Age-related osteoporosis with current pathological fracture, right lower leg, subsequent encounter for fracture with routine healing
Osteoporosis	M80061G	Age-related osteoporosis with current pathological fracture, right lower leg, subsequent encounter for fracture with delayed healing
Osteoporosis	M80061K	Age-related osteoporosis with current pathological fracture, right lower leg, subsequent encounter for fracture with nonunion

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Osteoporosis	M80061P	Age-related osteoporosis with current pathological fracture, right lower leg, subsequent encounter for fracture with malunion
Osteoporosis	M80061S	Age-related osteoporosis with current pathological fracture, right lower leg, sequela
Osteoporosis	M80062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture
Osteoporosis	M80062D	Age-related osteoporosis with current pathological fracture, left lower leg, subsequent encounter for fracture with routine healing
Osteoporosis	M80062G	Age-related osteoporosis with current pathological fracture, left lower leg, subsequent encounter for fracture with delayed healing
Osteoporosis	M80062K	Age-related osteoporosis with current pathological fracture, left lower leg, subsequent encounter for fracture with nonunion
Osteoporosis	M80062P	Age-related osteoporosis with current pathological fracture, left lower leg, subsequent encounter for fracture with malunion
Osteoporosis	M80062S	Age-related osteoporosis with current pathological fracture, left lower leg, sequela
Osteoporosis	M80069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture
Osteoporosis	M80069D	Age-related osteoporosis with current pathological fracture, unspecified lower leg, subsequent encounter for fracture with routine healing
Osteoporosis	M80069G	Age-related osteoporosis with current pathological fracture, unspecified lower leg, subsequent encounter for fracture with delayed healing
Osteoporosis	M80069K	Age-related osteoporosis with current pathological fracture, unspecified lower leg, subsequent encounter for fracture with nonunion
Osteoporosis	M80069P	Age-related osteoporosis with current pathological fracture, unspecified lower leg, subsequent encounter for fracture with malunion
Osteoporosis	M80069S	Age-related osteoporosis with current pathological fracture, unspecified lower leg, sequela
Osteoporosis	M80071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture
Osteoporosis	M80071D	Age-related osteoporosis with current pathological fracture, right ankle and foot, subsequent encounter for fracture with routine healing
Osteoporosis	M80071G	Age-related osteoporosis with current pathological fracture, right ankle and foot, subsequent encounter for fracture with delayed healing
Osteoporosis	M80071K	Age-related osteoporosis with current pathological fracture, right ankle and foot, subsequent encounter for fracture with nonunion
Osteoporosis	M80071P	Age-related osteoporosis with current pathological fracture, right ankle and foot, subsequent encounter for fracture with malunion
Osteoporosis	M80071S	Age-related osteoporosis with current pathological fracture, right ankle and foot, sequela
Osteoporosis	M80072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture
Osteoporosis	M80072D	Age-related osteoporosis with current pathological fracture, left ankle and foot, subsequent encounter for fracture with routine healing
Osteoporosis	M80072G	Age-related osteoporosis with current pathological fracture, left ankle and foot, subsequent encounter for fracture with delayed healing
Osteoporosis	M80072K	Age-related osteoporosis with current pathological fracture, left ankle and foot, subsequent encounter for fracture with nonunion
Osteoporosis	M80072P	Age-related osteoporosis with current pathological fracture, left ankle and foot, subsequent encounter for fracture with malunion
Osteoporosis	M80072S	Age-related osteoporosis with current pathological fracture, left ankle and foot, sequela
Osteoporosis	M80079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Osteoporosis	M80079D	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, subsequent encounter for fracture with routine healing
Osteoporosis	M80079G	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, subsequent encounter for fracture with delayed healing
Osteoporosis	M80079K	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, subsequent encounter for fracture with nonunion
Osteoporosis	M80079P	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, subsequent encounter for fracture with malunion
Osteoporosis	M80079S	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, sequela
Osteoporosis	M8008XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture
Osteoporosis	M8008XD	Age-related osteoporosis with current pathological fracture, vertebra(e), subsequent encounter for fracture with routine healing
Osteoporosis	M8008XG	Age-related osteoporosis with current pathological fracture, vertebra(e), subsequent encounter for fracture with delayed healing
Osteoporosis	M8008XK	Age-related osteoporosis with current pathological fracture, vertebra(e), subsequent encounter for fracture with nonunion
Osteoporosis	M8008XP	Age-related osteoporosis with current pathological fracture, vertebra(e), subsequent encounter for fracture with malunion
Osteoporosis	M8008XS	Age-related osteoporosis with current pathological fracture, vertebra(e), sequela
Osteoporosis	M800AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture
Osteoporosis	M800AXD	Age-related osteoporosis with current pathological fracture, other site, subsequent encounter for fracture with routine healing
Osteoporosis	M800AXG	Age-related osteoporosis with current pathological fracture, other site, subsequent encounter for fracture with delayed healing
Osteoporosis	M800AXK	Age-related osteoporosis with current pathological fracture, other site, subsequent encounter for fracture with nonunion
Osteoporosis	M800AXP	Age-related osteoporosis with current pathological fracture, other site, subsequent encounter for fracture with malunion
Osteoporosis	M800AXS	Age-related osteoporosis with current pathological fracture, other site, sequela
Osteoporosis	M800B1A	Age-related osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture
Osteoporosis	M800B1D	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with routine healing
Osteoporosis	M800B1G	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with delayed healing
Osteoporosis	M800B1K	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with nonunion
Osteoporosis	M800B1P	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with malunion
Osteoporosis	M800B1S	Age-related osteoporosis with current pathological fracture, right pelvis, sequela
Osteoporosis	M800B2A	Age-related osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture
Osteoporosis	M800B2D	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with routine healing
Osteoporosis	M800B2G	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with delayed healing
Osteoporosis	M800B2K	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with nonunion
Osteoporosis	M800B2P	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with malunion

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Osteoporosis	M800B2S	Age-related osteoporosis with current pathological fracture, left pelvis, sequela
Osteoporosis	M800B9A	Age-related osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture
Osteoporosis	M800B9D	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with routine healing
Osteoporosis	M800B9G	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with delayed healing
Osteoporosis	M800B9K	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with nonunion
Osteoporosis	M800B9P	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with malunion
Osteoporosis	M800B9S	Age-related osteoporosis with current pathological fracture, unspecified pelvis, sequela
Osteoporosis	M8080XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture
Osteoporosis	M8080XD	Other osteoporosis with current pathological fracture, unspecified site, subsequent encounter for fracture with routine healing
Osteoporosis	M8080XG	Other osteoporosis with current pathological fracture, unspecified site, subsequent encounter for fracture with delayed healing
Osteoporosis	M8080XK	Other osteoporosis with current pathological fracture, unspecified site, subsequent encounter for fracture with nonunion
Osteoporosis	M8080XP	Other osteoporosis with current pathological fracture, unspecified site, subsequent encounter for fracture with malunion
Osteoporosis	M8080XS	Other osteoporosis with current pathological fracture, unspecified site, sequela
Osteoporosis	M80811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture
Osteoporosis	M80811D	Other osteoporosis with current pathological fracture, right shoulder, subsequent encounter for fracture with routine healing
Osteoporosis	M80811G	Other osteoporosis with current pathological fracture, right shoulder, subsequent encounter for fracture with delayed healing
Osteoporosis	M80811K	Other osteoporosis with current pathological fracture, right shoulder, subsequent encounter for fracture with nonunion
Osteoporosis	M80811P	Other osteoporosis with current pathological fracture, right shoulder, subsequent encounter for fracture with malunion
Osteoporosis	M80811S	Other osteoporosis with current pathological fracture, right shoulder, sequela
Osteoporosis	M80812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture
Osteoporosis	M80812D	Other osteoporosis with current pathological fracture, left shoulder, subsequent encounter for fracture with routine healing
Osteoporosis	M80812G	Other osteoporosis with current pathological fracture, left shoulder, subsequent encounter for fracture with delayed healing
Osteoporosis	M80812K	Other osteoporosis with current pathological fracture, left shoulder, subsequent encounter for fracture with nonunion
Osteoporosis	M80812P	Other osteoporosis with current pathological fracture, left shoulder, subsequent encounter for fracture with malunion
Osteoporosis	M80812S	Other osteoporosis with current pathological fracture, left shoulder, sequela
Osteoporosis	M80819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture
Osteoporosis	M80819D	Other osteoporosis with current pathological fracture, unspecified shoulder, subsequent encounter for fracture with routine healing
Osteoporosis	M80819G	Other osteoporosis with current pathological fracture, unspecified shoulder, subsequent encounter for fracture with delayed healing

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Osteoporosis	M80819K	Other osteoporosis with current pathological fracture, unspecified shoulder, subsequent encounter for fracture with nonunion
Osteoporosis	M80819P	Other osteoporosis with current pathological fracture, unspecified shoulder, subsequent encounter for fracture with malunion
Osteoporosis	M80819S	Other osteoporosis with current pathological fracture, unspecified shoulder, sequela
Osteoporosis	M80821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture
Osteoporosis	M80821D	Other osteoporosis with current pathological fracture, right humerus, subsequent encounter for fracture with routine healing
Osteoporosis	M80821G	Other osteoporosis with current pathological fracture, right humerus, subsequent encounter for fracture with delayed healing
Osteoporosis	M80821K	Other osteoporosis with current pathological fracture, right humerus, subsequent encounter for fracture with nonunion
Osteoporosis	M80821P	Other osteoporosis with current pathological fracture, right humerus, subsequent encounter for fracture with malunion
Osteoporosis	M80821S	Other osteoporosis with current pathological fracture, right humerus, sequela
Osteoporosis	M80822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture
Osteoporosis	M80822D	Other osteoporosis with current pathological fracture, left humerus, subsequent encounter for fracture with routine healing
Osteoporosis	M80822G	Other osteoporosis with current pathological fracture, left humerus, subsequent encounter for fracture with delayed healing
Osteoporosis	M80822K	Other osteoporosis with current pathological fracture, left humerus, subsequent encounter for fracture with nonunion
Osteoporosis	M80822P	Other osteoporosis with current pathological fracture, left humerus, subsequent encounter for fracture with malunion
Osteoporosis	M80822S	Other osteoporosis with current pathological fracture, left humerus, sequela
Osteoporosis	M80829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture
Osteoporosis	M80829D	Other osteoporosis with current pathological fracture, unspecified humerus, subsequent encounter for fracture with routine healing
Osteoporosis	M80829G	Other osteoporosis with current pathological fracture, unspecified humerus, subsequent encounter for fracture with delayed healing
Osteoporosis	M80829K	Other osteoporosis with current pathological fracture, unspecified humerus, subsequent encounter for fracture with nonunion
Osteoporosis	M80829P	Other osteoporosis with current pathological fracture, unspecified humerus, subsequent encounter for fracture with malunion
Osteoporosis	M80829S	Other osteoporosis with current pathological fracture, unspecified humerus, sequela
Osteoporosis	M80831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture
Osteoporosis	M80831D	Other osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with routine healing
Osteoporosis	M80831G	Other osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with delayed healing
Osteoporosis	M80831K	Other osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with nonunion
Osteoporosis	M80831P	Other osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with malunion
Osteoporosis	M80831S	Other osteoporosis with current pathological fracture, right forearm, sequela
Osteoporosis	M80832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Osteoporosis	M80832D	Other osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with routine healing
Osteoporosis	M80832G	Other osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with delayed healing
Osteoporosis	M80832K	Other osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with nonunion
Osteoporosis	M80832P	Other osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with malunion
Osteoporosis	M80832S	Other osteoporosis with current pathological fracture, left forearm, sequela
Osteoporosis	M80839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture
Osteoporosis	M80839D	Other osteoporosis with current pathological fracture, unspecified forearm, subsequent encounter for fracture with routine healing
Osteoporosis	M80839G	Other osteoporosis with current pathological fracture, unspecified forearm, subsequent encounter for fracture with delayed healing
Osteoporosis	M80839K	Other osteoporosis with current pathological fracture, unspecified forearm, subsequent encounter for fracture with nonunion
Osteoporosis	M80839P	Other osteoporosis with current pathological fracture, unspecified forearm, subsequent encounter for fracture with malunion
Osteoporosis	M80839S	Other osteoporosis with current pathological fracture, unspecified forearm, sequela
Osteoporosis	M80841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture
Osteoporosis	M80841D	Other osteoporosis with current pathological fracture, right hand, subsequent encounter for fracture with routine healing
Osteoporosis	M80841G	Other osteoporosis with current pathological fracture, right hand, subsequent encounter for fracture with delayed healing
Osteoporosis	M80841K	Other osteoporosis with current pathological fracture, right hand, subsequent encounter for fracture with nonunion
Osteoporosis	M80841P	Other osteoporosis with current pathological fracture, right hand, subsequent encounter for fracture with malunion
Osteoporosis	M80841S	Other osteoporosis with current pathological fracture, right hand, sequela
Osteoporosis	M80842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture
Osteoporosis	M80842D	Other osteoporosis with current pathological fracture, left hand, subsequent encounter for fracture with routine healing
Osteoporosis	M80842G	Other osteoporosis with current pathological fracture, left hand, subsequent encounter for fracture with delayed healing
Osteoporosis	M80842K	Other osteoporosis with current pathological fracture, left hand, subsequent encounter for fracture with nonunion
Osteoporosis	M80842P	Other osteoporosis with current pathological fracture, left hand, subsequent encounter for fracture with malunion
Osteoporosis	M80842S	Other osteoporosis with current pathological fracture, left hand, sequela
Osteoporosis	M80849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture
Osteoporosis	M80849D	Other osteoporosis with current pathological fracture, unspecified hand, subsequent encounter for fracture with routine healing
Osteoporosis	M80849G	Other osteoporosis with current pathological fracture, unspecified hand, subsequent encounter for fracture with delayed healing
Osteoporosis	M80849K	Other osteoporosis with current pathological fracture, unspecified hand, subsequent encounter for fracture with nonunion
Osteoporosis	M80849P	Other osteoporosis with current pathological fracture, unspecified hand, subsequent encounter for fracture with malunion

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Osteoporosis	M80849S	Other osteoporosis with current pathological fracture, unspecified hand, sequela
Osteoporosis	M80851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture
Osteoporosis	M80851D	Other osteoporosis with current pathological fracture, right femur, subsequent encounter for fracture with routine healing
Osteoporosis	M80851G	Other osteoporosis with current pathological fracture, right femur, subsequent encounter for fracture with delayed healing
Osteoporosis	M80851K	Other osteoporosis with current pathological fracture, right femur, subsequent encounter for fracture with nonunion
Osteoporosis	M80851P	Other osteoporosis with current pathological fracture, right femur, subsequent encounter for fracture with malunion
Osteoporosis	M80851S	Other osteoporosis with current pathological fracture, right femur, sequela
Osteoporosis	M80852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture
Osteoporosis	M80852D	Other osteoporosis with current pathological fracture, left femur, subsequent encounter for fracture with routine healing
Osteoporosis	M80852G	Other osteoporosis with current pathological fracture, left femur, subsequent encounter for fracture with delayed healing
Osteoporosis	M80852K	Other osteoporosis with current pathological fracture, left femur, subsequent encounter for fracture with nonunion
Osteoporosis	M80852P	Other osteoporosis with current pathological fracture, left femur, subsequent encounter for fracture with malunion
Osteoporosis	M80852S	Other osteoporosis with current pathological fracture, left femur, sequela
Osteoporosis	M80859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture
Osteoporosis	M80859D	Other osteoporosis with current pathological fracture, unspecified femur, subsequent encounter for fracture with routine healing
Osteoporosis	M80859G	Other osteoporosis with current pathological fracture, unspecified femur, subsequent encounter for fracture with delayed healing
Osteoporosis	M80859K	Other osteoporosis with current pathological fracture, unspecified femur, subsequent encounter for fracture with nonunion
Osteoporosis	M80859P	Other osteoporosis with current pathological fracture, unspecified femur, subsequent encounter for fracture with malunion
Osteoporosis	M80859S	Other osteoporosis with current pathological fracture, unspecified femur, sequela
Osteoporosis	M80861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture
Osteoporosis	M80861D	Other osteoporosis with current pathological fracture, right lower leg, subsequent encounter for fracture with routine healing
Osteoporosis	M80861G	Other osteoporosis with current pathological fracture, right lower leg, subsequent encounter for fracture with delayed healing
Osteoporosis	M80861K	Other osteoporosis with current pathological fracture, right lower leg, subsequent encounter for fracture with nonunion
Osteoporosis	M80861P	Other osteoporosis with current pathological fracture, right lower leg, subsequent encounter for fracture with malunion
Osteoporosis	M80861S	Other osteoporosis with current pathological fracture, right lower leg, sequela
Osteoporosis	M80862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture
Osteoporosis	M80862D	Other osteoporosis with current pathological fracture, left lower leg, subsequent encounter for fracture with routine healing
Osteoporosis	M80862G	Other osteoporosis with current pathological fracture, left lower leg, subsequent encounter for fracture with delayed healing
Osteoporosis	M80862K	Other osteoporosis with current pathological fracture, left lower leg, subsequent encounter for fracture with nonunion

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Osteoporosis	M80862P	Other osteoporosis with current pathological fracture, left lower leg, subsequent encounter for fracture with malunion
Osteoporosis	M80862S	Other osteoporosis with current pathological fracture, left lower leg, sequela
Osteoporosis	M80869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture
Osteoporosis	M80869D	Other osteoporosis with current pathological fracture, unspecified lower leg, subsequent encounter for fracture with routine healing
Osteoporosis	M80869G	Other osteoporosis with current pathological fracture, unspecified lower leg, subsequent encounter for fracture with delayed healing
Osteoporosis	M80869K	Other osteoporosis with current pathological fracture, unspecified lower leg, subsequent encounter for fracture with nonunion
Osteoporosis	M80869P	Other osteoporosis with current pathological fracture, unspecified lower leg, subsequent encounter for fracture with malunion
Osteoporosis	M80869S	Other osteoporosis with current pathological fracture, unspecified lower leg, sequela
Osteoporosis	M80871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture
Osteoporosis	M80871D	Other osteoporosis with current pathological fracture, right ankle and foot, subsequent encounter for fracture with routine healing
Osteoporosis	M80871G	Other osteoporosis with current pathological fracture, right ankle and foot, subsequent encounter for fracture with delayed healing
Osteoporosis	M80871K	Other osteoporosis with current pathological fracture, right ankle and foot, subsequent encounter for fracture with nonunion
Osteoporosis	M80871P	Other osteoporosis with current pathological fracture, right ankle and foot, subsequent encounter for fracture with malunion
Osteoporosis	M80871S	Other osteoporosis with current pathological fracture, right ankle and foot, sequela
Osteoporosis	M80872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture
Osteoporosis	M80872D	Other osteoporosis with current pathological fracture, left ankle and foot, subsequent encounter for fracture with routine healing
Osteoporosis	M80872G	Other osteoporosis with current pathological fracture, left ankle and foot, subsequent encounter for fracture with delayed healing
Osteoporosis	M80872K	Other osteoporosis with current pathological fracture, left ankle and foot, subsequent encounter for fracture with nonunion
Osteoporosis	M80872P	Other osteoporosis with current pathological fracture, left ankle and foot, subsequent encounter for fracture with malunion
Osteoporosis	M80872S	Other osteoporosis with current pathological fracture, left ankle and foot, sequela
Osteoporosis	M80879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture
Osteoporosis	M80879D	Other osteoporosis with current pathological fracture, unspecified ankle and foot, subsequent encounter for fracture with routine healing
Osteoporosis	M80879G	Other osteoporosis with current pathological fracture, unspecified ankle and foot, subsequent encounter for fracture with delayed healing
Osteoporosis	M80879K	Other osteoporosis with current pathological fracture, unspecified ankle and foot, subsequent encounter for fracture with nonunion
Osteoporosis	M80879P	Other osteoporosis with current pathological fracture, unspecified ankle and foot, subsequent encounter for fracture with malunion
Osteoporosis	M80879S	Other osteoporosis with current pathological fracture, unspecified ankle and foot, sequela
Osteoporosis	M8088XA	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture
Osteoporosis	M8088XD	Other osteoporosis with current pathological fracture, vertebra(e), subsequent encounter for fracture with routine healing

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Osteoporosis	M8088XG	Other osteoporosis with current pathological fracture, vertebra(e), subsequent encounter for fracture with delayed healing
Osteoporosis	M8088XK	Other osteoporosis with current pathological fracture, vertebra(e), subsequent encounter for fracture with nonunion
Osteoporosis	M8088XP	Other osteoporosis with current pathological fracture, vertebra(e), subsequent encounter for fracture with malunion
Osteoporosis	M8088XS	Other osteoporosis with current pathological fracture, vertebra(e), sequela
Osteoporosis	M808AXA	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture
Osteoporosis	M808AXD	Other osteoporosis with current pathological fracture, other site, subsequent encounter for fracture with routine healing
Osteoporosis	M808AXG	Other osteoporosis with current pathological fracture, other site, subsequent encounter for fracture with delayed healing
Osteoporosis	M808AXK	Other osteoporosis with current pathological fracture, other site, subsequent encounter for fracture with nonunion
Osteoporosis	M808AXP	Other osteoporosis with current pathological fracture, other site, subsequent encounter for fracture with malunion
Osteoporosis	M808AXS	Other osteoporosis with current pathological fracture, other site, sequela
Osteoporosis	M808B1A	Other osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture
Osteoporosis	M808B1D	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with routine healing
Osteoporosis	M808B1G	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with delayed healing
Osteoporosis	M808B1K	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with nonunion
Osteoporosis	M808B1P	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with malunion
Osteoporosis	M808B1S	Other osteoporosis with current pathological fracture, right pelvis, sequela
Osteoporosis	M808B2A	Other osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture
Osteoporosis	M808B2D	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with routine healing
Osteoporosis	M808B2G	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with delayed healing
Osteoporosis	M808B2K	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with nonunion
Osteoporosis	M808B2P	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with malunion
Osteoporosis	M808B2S	Other osteoporosis with current pathological fracture, left pelvis, sequela
Osteoporosis	M808B9A	Other osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture
Osteoporosis	M808B9D	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with routine healing
Osteoporosis	M808B9G	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with delayed healing
Osteoporosis	M808B9K	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with nonunion
Osteoporosis	M808B9P	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with malunion
Osteoporosis	M808B9S	Other osteoporosis with current pathological fracture, unspecified pelvis, sequela
Osteoporosis	M810	Age-related osteoporosis without current pathological fracture

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Osteoporosis	M816	Localized osteoporosis [Lequesne]
Osteoporosis	M818	Other osteoporosis without current pathological fracture
Osteoporosis	Z13820	Encounter for screening for osteoporosis
Cardiovascular Dz	I200	Unstable angina
Cardiovascular Dz	I201	Angina pectoris with documented spasm
Cardiovascular Dz	I202	Refractory angina pectoris
Cardiovascular Dz	I208	Other forms of angina pectoris
Cardiovascular Dz	I2081	Angina pectoris with coronary microvascular dysfunction
Cardiovascular Dz	I2089	Other forms of angina pectoris
Cardiovascular Dz	I209	Angina pectoris, unspecified
Cardiovascular Dz	I2101	ST elevation (STEMI) myocardial infarction involving left main coronary artery
Cardiovascular Dz	I2102	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery
Cardiovascular Dz	I2109	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall
Cardiovascular Dz	I2111	ST elevation (STEMI) myocardial infarction involving right coronary artery
Cardiovascular Dz	I2119	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall
Cardiovascular Dz	I2121	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery
Cardiovascular Dz	I2129	ST elevation (STEMI) myocardial infarction involving other sites
Cardiovascular Dz	I213	ST elevation (STEMI) myocardial infarction of unspecified site
Cardiovascular Dz	I214	Non-ST elevation (NSTEMI) myocardial infarction
Cardiovascular Dz	I219	Acute myocardial infarction, unspecified
Cardiovascular Dz	I21A1	Myocardial infarction type 2
Cardiovascular Dz	I21A9	Other myocardial infarction type
Cardiovascular Dz	I21B	Myocardial infarction with coronary microvascular dysfunction
Cardiovascular Dz	I220	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall
Cardiovascular Dz	I221	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall
Cardiovascular Dz	I222	Subsequent non-ST elevation (NSTEMI) myocardial infarction
Cardiovascular Dz	I228	Subsequent ST elevation (STEMI) myocardial infarction of other sites
Cardiovascular Dz	I229	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site
Cardiovascular Dz	I230	Hemopericardium as current complication following acute myocardial infarction
Cardiovascular Dz	I231	Atrial septal defect as current complication following acute myocardial infarction
Cardiovascular Dz	I232	Ventricular septal defect as current complication following acute myocardial infarction
Cardiovascular Dz	I233	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction
Cardiovascular Dz	I234	Rupture of chordae tendineae as current complication following acute myocardial infarction
Cardiovascular Dz	I235	Rupture of papillary muscle as current complication following acute myocardial infarction
Cardiovascular Dz	I236	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction
Cardiovascular Dz	I237	Postinfarction angina
Cardiovascular Dz	I238	Other current complications following acute myocardial infarction
Cardiovascular Dz	I249	Acute ischemic heart disease, unspecified
Cardiovascular Dz	I2510	Atherosclerotic heart disease of native coronary artery without angina pectoris

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Cardiovascular Dz	I25110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris
Cardiovascular Dz	I25111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm
Cardiovascular Dz	I25112	Atherosclerotic heart disease of native coronary artery with refractory angina pectoris
Cardiovascular Dz	I25118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris
Cardiovascular Dz	I25119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris
Cardiovascular Dz	I252	Old myocardial infarction
Cardiovascular Dz	I253	Aneurysm of heart
Cardiovascular Dz	I2541	Coronary artery aneurysm
Cardiovascular Dz	I2542	Coronary artery dissection
Cardiovascular Dz	I255	Ischemic cardiomyopathy
Cardiovascular Dz	I256	Silent myocardial ischemia
Cardiovascular Dz	I25700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris
Cardiovascular Dz	I25701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm
Cardiovascular Dz	I25702	Atherosclerosis of coronary artery bypass graft(s), unspecified, with refractory angina pectoris
Cardiovascular Dz	I25708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris
Cardiovascular Dz	I25709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris
Cardiovascular Dz	I25710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris
Cardiovascular Dz	I25711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm
Cardiovascular Dz	I25712	Atherosclerosis of autologous vein coronary artery bypass graft(s) with refractory angina pectoris
Cardiovascular Dz	I25718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris
Cardiovascular Dz	I25719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris
Cardiovascular Dz	I25720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris
Cardiovascular Dz	I25721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm
Cardiovascular Dz	I25722	Atherosclerosis of autologous artery coronary artery bypass graft(s) with refractory angina pectoris
Cardiovascular Dz	I25728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris
Cardiovascular Dz	I25729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris
Cardiovascular Dz	I25730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris
Cardiovascular Dz	I25731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm
Cardiovascular Dz	I25732	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with refractory angina pectoris
Cardiovascular Dz	I25738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris
Cardiovascular Dz	I25739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris
Cardiovascular Dz	I25750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina
Cardiovascular Dz	I25751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm
Cardiovascular Dz	I25752	Atherosclerosis of native coronary artery of transplanted heart with refractory angina pectoris

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Cardiovascular Dz	I25758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris
Cardiovascular Dz	I25759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris
Cardiovascular Dz	I25760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina
Cardiovascular Dz	I25761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm
Cardiovascular Dz	I25762	Atherosclerosis of bypass graft of coronary artery of transplanted heart with refractory angina pectoris
Cardiovascular Dz	I25768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris
Cardiovascular Dz	I25769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris
Cardiovascular Dz	I25790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris
Cardiovascular Dz	I25791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm
Cardiovascular Dz	I25792	Atherosclerosis of other coronary artery bypass graft(s) with refractory angina pectoris
Cardiovascular Dz	I25798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris
Cardiovascular Dz	I25799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris
Cardiovascular Dz	I25810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris
Cardiovascular Dz	I25811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris
Cardiovascular Dz	I25812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris
Cardiovascular Dz	I2582	Chronic total occlusion of coronary artery
Cardiovascular Dz	I2583	Coronary atherosclerosis due to lipid rich plaque
Cardiovascular Dz	I2584	Coronary atherosclerosis due to calcified coronary lesion
Cardiovascular Dz	I2585	Chronic coronary microvascular dysfunction
Cardiovascular Dz	I2589	Other forms of chronic ischemic heart disease
Cardiovascular Dz	I469	Cardiac arrest, cause unspecified
Cardiovascular Dz	I519	Heart disease, unspecified
Cardiovascular Dz	I5189	Other ill-defined heart diseases
Cardiovascular Dz	I219	Acute myocardial infarction, unspecified
Cardiovascular Dz	I21A1	Myocardial infarction type 2
Cardiovascular Dz	I21A9	Other myocardial infarction type
Cerebrovascular Dz	G468	Other vascular syndromes of brain in cerebrovascular diseases
Cerebrovascular Dz	I6781	Acute cerebrovascular insufficiency
Cerebrovascular Dz	I67858	Other hereditary cerebrovascular disease
Cerebrovascular Dz	I6789	Other cerebrovascular disease
Cerebrovascular Dz	I679	Cerebrovascular disease, unspecified
Cerebrovascular Dz	I688	Other cerebrovascular disorders in diseases classified elsewhere
Cerebrovascular Dz	I6980	Unspecified sequelae of other cerebrovascular disease
Cerebrovascular Dz	I69810	Attention and concentration deficit following other cerebrovascular disease
Cerebrovascular Dz	I69811	Memory deficit following other cerebrovascular disease
Cerebrovascular Dz	I69812	Visuospatial deficit and spatial neglect following other cerebrovascular disease
Cerebrovascular Dz	I69813	Psychomotor deficit following other cerebrovascular disease
Cerebrovascular Dz	I69814	Frontal lobe and executive function deficit following other cerebrovascular disease

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Cerebrovascular Dz	I69815	Cognitive social or emotional deficit following other cerebrovascular disease
Cerebrovascular Dz	I69818	Other symptoms and signs involving cognitive functions following other cerebrovascular disease
Cerebrovascular Dz	I69819	Unspecified symptoms and signs involving cognitive functions following other cerebrovascular disease
Cerebrovascular Dz	I69820	Aphasia following other cerebrovascular disease
Cerebrovascular Dz	I69821	Dysphasia following other cerebrovascular disease
Cerebrovascular Dz	I69822	Dysarthria following other cerebrovascular disease
Cerebrovascular Dz	I69823	Fluency disorder following other cerebrovascular disease
Cerebrovascular Dz	I69828	Other speech and language deficits following other cerebrovascular disease
Cerebrovascular Dz	I69831	Monoplegia of upper limb following other cerebrovascular disease affecting right dominant side
Cerebrovascular Dz	I69832	Monoplegia of upper limb following other cerebrovascular disease affecting left dominant side
Cerebrovascular Dz	I69833	Monoplegia of upper limb following other cerebrovascular disease affecting right non-dominant side
Cerebrovascular Dz	I69834	Monoplegia of upper limb following other cerebrovascular disease affecting left non-dominant side
Cerebrovascular Dz	I69839	Monoplegia of upper limb following other cerebrovascular disease affecting unspecified side
Cerebrovascular Dz	I69841	Monoplegia of lower limb following other cerebrovascular disease affecting right dominant side
Cerebrovascular Dz	I69842	Monoplegia of lower limb following other cerebrovascular disease affecting left dominant side
Cerebrovascular Dz	I69843	Monoplegia of lower limb following other cerebrovascular disease affecting right non-dominant side
Cerebrovascular Dz	I69844	Monoplegia of lower limb following other cerebrovascular disease affecting left non-dominant side
Cerebrovascular Dz	I69849	Monoplegia of lower limb following other cerebrovascular disease affecting unspecified side
Cerebrovascular Dz	I69851	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right dominant side
Cerebrovascular Dz	I69852	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left dominant side
Cerebrovascular Dz	I69853	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right non-dominant side
Cerebrovascular Dz	I69854	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left non-dominant side
Cerebrovascular Dz	I69859	Hemiplegia and hemiparesis following other cerebrovascular disease affecting unspecified side
Cerebrovascular Dz	I69861	Other paralytic syndrome following other cerebrovascular disease affecting right dominant side
Cerebrovascular Dz	I69862	Other paralytic syndrome following other cerebrovascular disease affecting left dominant side
Cerebrovascular Dz	I69863	Other paralytic syndrome following other cerebrovascular disease affecting right non-dominant side
Cerebrovascular Dz	I69864	Other paralytic syndrome following other cerebrovascular disease affecting left non-dominant side
Cerebrovascular Dz	I69865	Other paralytic syndrome following other cerebrovascular disease, bilateral
Cerebrovascular Dz	I69869	Other paralytic syndrome following other cerebrovascular disease affecting unspecified side
Cerebrovascular Dz	I69890	Apraxia following other cerebrovascular disease
Cerebrovascular Dz	I69891	Dysphagia following other cerebrovascular disease
Cerebrovascular Dz	I69892	Facial weakness following other cerebrovascular disease
Cerebrovascular Dz	I69893	Ataxia following other cerebrovascular disease
Cerebrovascular Dz	I69898	Other sequelae of other cerebrovascular disease
Cerebrovascular Dz	I6990	Unspecified sequelae of unspecified cerebrovascular disease
Cerebrovascular Dz	I6991	Cognitive deficits following unsp cerebrovascular disease
Cerebrovascular Dz	I69910	Attention and concentration deficit following unspecified cerebrovascular disease
Cerebrovascular Dz	I69911	Memory deficit following unspecified cerebrovascular disease
Cerebrovascular Dz	I69912	Visuospatial deficit and spatial neglect following unspecified cerebrovascular disease

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Cerebrovascular Dz	I69913	Psychomotor deficit following unspecified cerebrovascular disease
Cerebrovascular Dz	I69914	Frontal lobe and executive function deficit following unspecified cerebrovascular disease
Cerebrovascular Dz	I69915	Cognitive social or emotional deficit following unspecified cerebrovascular disease
Cerebrovascular Dz	I69918	Other symptoms and signs involving cognitive functions following unspecified cerebrovascular disease
Cerebrovascular Dz	I69919	Unspecified symptoms and signs involving cognitive functions following unspecified cerebrovascular disease
Cerebrovascular Dz	I69920	Aphasia following unspecified cerebrovascular disease
Cerebrovascular Dz	I69921	Dysphasia following unspecified cerebrovascular disease
Cerebrovascular Dz	I69922	Dysarthria following unspecified cerebrovascular disease
Cerebrovascular Dz	I69923	Fluency disorder following unspecified cerebrovascular disease
Cerebrovascular Dz	I69928	Other speech and language deficits following unspecified cerebrovascular disease
Cerebrovascular Dz	I69931	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right dominant side
Cerebrovascular Dz	I69932	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left dominant side
Cerebrovascular Dz	I69933	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right non-dominant side
Cerebrovascular Dz	I69934	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left non-dominant side
Cerebrovascular Dz	I69939	Monoplegia of upper limb following unspecified cerebrovascular disease affecting unspecified side
Cerebrovascular Dz	I69941	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right dominant side
Cerebrovascular Dz	I69942	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left dominant side
Cerebrovascular Dz	I69943	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right non-dominant side
Cerebrovascular Dz	I69944	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left non-dominant side
Cerebrovascular Dz	I69949	Monoplegia of lower limb following unspecified cerebrovascular disease affecting unspecified side
Cerebrovascular Dz	I69951	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right dominant side
Cerebrovascular Dz	I69952	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left dominant side
Cerebrovascular Dz	I69953	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right non-dominant side
Cerebrovascular Dz	I69954	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left non-dominant side
Cerebrovascular Dz	I69959	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting unspecified side
Cerebrovascular Dz	Z8673	Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits
Cerebrovascular Dz	G463	Brain stem stroke syndrome
Cerebrovascular Dz	G464	Cerebellar stroke syndrome
DVT/PE	I240	Acute coronary thrombosis not resulting in myocardial infarction
DVT/PE	I7410	Embolism and thrombosis of unspecified parts of aorta
DVT/PE	I7411	Embolism and thrombosis of thoracic aorta
DVT/PE	I7419	Embolism and thrombosis of other parts of aorta
DVT/PE	I742	Embolism and thrombosis of arteries of the upper extremities
DVT/PE	I743	Embolism and thrombosis of arteries of the lower extremities

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
DVT/PE	I744	Embolism and thrombosis of arteries of extremities, unspecified
DVT/PE	I745	Embolism and thrombosis of iliac artery
DVT/PE	I748	Embolism and thrombosis of other arteries
DVT/PE	I749	Embolism and thrombosis of unspecified artery
DVT/PE	I81	Portal vein thrombosis
DVT/PE	I82210	Acute embolism and thrombosis of superior vena cava
DVT/PE	I82211	Chronic embolism and thrombosis of superior vena cava
DVT/PE	I82220	Acute embolism and thrombosis of inferior vena cava
DVT/PE	I82221	Chronic embolism and thrombosis of inferior vena cava
DVT/PE	I82290	Acute embolism and thrombosis of other thoracic veins
DVT/PE	I82291	Chronic embolism and thrombosis of other thoracic veins
DVT/PE	I823	Embolism and thrombosis of renal vein
DVT/PE	I82401	Acute embolism and thrombosis of unspecified deep veins of right lower extremity
DVT/PE	I82402	Acute embolism and thrombosis of unspecified deep veins of left lower extremity
DVT/PE	I82403	Acute embolism and thrombosis of unspecified deep veins of lower extremity, bilateral
DVT/PE	I82409	Acute embolism and thrombosis of unspecified deep veins of unspecified lower extremity
DVT/PE	I82411	Acute embolism and thrombosis of right femoral vein
DVT/PE	I82412	Acute embolism and thrombosis of left femoral vein
DVT/PE	I82413	Acute embolism and thrombosis of femoral vein, bilateral
DVT/PE	I82419	Acute embolism and thrombosis of unspecified femoral vein
DVT/PE	I82421	Acute embolism and thrombosis of right iliac vein
DVT/PE	I82422	Acute embolism and thrombosis of left iliac vein
DVT/PE	I82423	Acute embolism and thrombosis of iliac vein, bilateral
DVT/PE	I82429	Acute embolism and thrombosis of unspecified iliac vein
DVT/PE	I82431	Acute embolism and thrombosis of right popliteal vein
DVT/PE	I82432	Acute embolism and thrombosis of left popliteal vein
DVT/PE	I82433	Acute embolism and thrombosis of popliteal vein, bilateral
DVT/PE	I82439	Acute embolism and thrombosis of unspecified popliteal vein
DVT/PE	I82441	Acute embolism and thrombosis of right tibial vein
DVT/PE	I82442	Acute embolism and thrombosis of left tibial vein
DVT/PE	I82443	Acute embolism and thrombosis of tibial vein, bilateral
DVT/PE	I82449	Acute embolism and thrombosis of unspecified tibial vein
DVT/PE	I82451	Acute embolism and thrombosis of right peroneal vein
DVT/PE	I82452	Acute embolism and thrombosis of left peroneal vein
DVT/PE	I82453	Acute embolism and thrombosis of peroneal vein, bilateral
DVT/PE	I82459	Acute embolism and thrombosis of unspecified peroneal vein
DVT/PE	I82461	Acute embolism and thrombosis of right calf muscular vein
DVT/PE	I82462	Acute embolism and thrombosis of left calf muscular vein
DVT/PE	I82463	Acute embolism and thrombosis of calf muscular vein, bilateral
DVT/PE	I82469	Acute embolism and thrombosis of unspecified calf muscular vein

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
DVT/PE	I82491	Acute embolism and thrombosis of other specified deep vein of right lower extremity
DVT/PE	I82492	Acute embolism and thrombosis of other specified deep vein of left lower extremity
DVT/PE	I82493	Acute embolism and thrombosis of other specified deep vein of lower extremity, bilateral
DVT/PE	I82499	Acute embolism and thrombosis of other specified deep vein of unspecified lower extremity
DVT/PE	I824Y1	Acute embolism and thrombosis of unspecified deep veins of right proximal lower extremity
DVT/PE	I824Y2	Acute embolism and thrombosis of unspecified deep veins of left proximal lower extremity
DVT/PE	I824Y3	Acute embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral
DVT/PE	I824Y9	Acute embolism and thrombosis of unspecified deep veins of unspecified proximal lower extremity
DVT/PE	I824Z1	Acute embolism and thrombosis of unspecified deep veins of right distal lower extremity
DVT/PE	I824Z2	Acute embolism and thrombosis of unspecified deep veins of left distal lower extremity
DVT/PE	I824Z3	Acute embolism and thrombosis of unspecified deep veins of distal lower extremity, bilateral
DVT/PE	I824Z9	Acute embolism and thrombosis of unspecified deep veins of unspecified distal lower extremity
DVT/PE	I82501	Chronic embolism and thrombosis of unspecified deep veins of right lower extremity
DVT/PE	I82502	Chronic embolism and thrombosis of unspecified deep veins of left lower extremity
DVT/PE	I82503	Chronic embolism and thrombosis of unspecified deep veins of lower extremity, bilateral
DVT/PE	I82509	Chronic embolism and thrombosis of unspecified deep veins of unspecified lower extremity
DVT/PE	I82511	Chronic embolism and thrombosis of right femoral vein
DVT/PE	I82512	Chronic embolism and thrombosis of left femoral vein
DVT/PE	I82513	Chronic embolism and thrombosis of femoral vein, bilateral
DVT/PE	I82519	Chronic embolism and thrombosis of unspecified femoral vein
DVT/PE	I82521	Chronic embolism and thrombosis of right iliac vein
DVT/PE	I82522	Chronic embolism and thrombosis of left iliac vein
DVT/PE	I82523	Chronic embolism and thrombosis of iliac vein, bilateral
DVT/PE	I82529	Chronic embolism and thrombosis of unspecified iliac vein
DVT/PE	I82531	Chronic embolism and thrombosis of right popliteal vein
DVT/PE	I82532	Chronic embolism and thrombosis of left popliteal vein
DVT/PE	I82533	Chronic embolism and thrombosis of popliteal vein, bilateral
DVT/PE	I82539	Chronic embolism and thrombosis of unspecified popliteal vein
DVT/PE	I82541	Chronic embolism and thrombosis of right tibial vein
DVT/PE	I82542	Chronic embolism and thrombosis of left tibial vein
DVT/PE	I82543	Chronic embolism and thrombosis of tibial vein, bilateral
DVT/PE	I82549	Chronic embolism and thrombosis of unspecified tibial vein
DVT/PE	I82551	Chronic embolism and thrombosis of right peroneal vein
DVT/PE	I82552	Chronic embolism and thrombosis of left peroneal vein
DVT/PE	I82553	Chronic embolism and thrombosis of peroneal vein, bilateral
DVT/PE	I82559	Chronic embolism and thrombosis of unspecified peroneal vein
DVT/PE	I82561	Chronic embolism and thrombosis of right calf muscular vein
DVT/PE	I82562	Chronic embolism and thrombosis of left calf muscular vein
DVT/PE	I82563	Chronic embolism and thrombosis of calf muscular vein, bilateral
DVT/PE	I82569	Chronic embolism and thrombosis of unspecified calf muscular vein

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
DVT/PE	I82591	Chronic embolism and thrombosis of other specified deep vein of right lower extremity
DVT/PE	I82592	Chronic embolism and thrombosis of other specified deep vein of left lower extremity
DVT/PE	I82593	Chronic embolism and thrombosis of other specified deep vein of lower extremity, bilateral
DVT/PE	I82599	Chronic embolism and thrombosis of other specified deep vein of unspecified lower extremity
DVT/PE	I825Y1	Chronic embolism and thrombosis of unspecified deep veins of right proximal lower extremity
DVT/PE	I825Y2	Chronic embolism and thrombosis of unspecified deep veins of left proximal lower extremity
DVT/PE	I825Y3	Chronic embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral
DVT/PE	I825Y9	Chronic embolism and thrombosis of unspecified deep veins of unspecified proximal lower extremity
DVT/PE	I825Z1	Chronic embolism and thrombosis of unspecified deep veins of right distal lower extremity
DVT/PE	I825Z2	Chronic embolism and thrombosis of unspecified deep veins of left distal lower extremity
DVT/PE	I825Z3	Chronic embolism and thrombosis of unspecified deep veins of distal lower extremity, bilateral
DVT/PE	I825Z9	Chronic embolism and thrombosis of unspecified deep veins of unspecified distal lower extremity
DVT/PE	I82601	Acute embolism and thrombosis of unspecified veins of right upper extremity
DVT/PE	I82602	Acute embolism and thrombosis of unspecified veins of left upper extremity
DVT/PE	I82603	Acute embolism and thrombosis of unspecified veins of upper extremity, bilateral
DVT/PE	I82609	Acute embolism and thrombosis of unspecified veins of unspecified upper extremity
DVT/PE	I82611	Acute embolism and thrombosis of superficial veins of right upper extremity
DVT/PE	I82612	Acute embolism and thrombosis of superficial veins of left upper extremity
DVT/PE	I82613	Acute embolism and thrombosis of superficial veins of upper extremity, bilateral
DVT/PE	I82619	Acute embolism and thrombosis of superficial veins of unspecified upper extremity
DVT/PE	I82621	Acute embolism and thrombosis of deep veins of right upper extremity
DVT/PE	I82622	Acute embolism and thrombosis of deep veins of left upper extremity
DVT/PE	I82623	Acute embolism and thrombosis of deep veins of upper extremity, bilateral
DVT/PE	I82629	Acute embolism and thrombosis of deep veins of unspecified upper extremity
DVT/PE	I82701	Chronic embolism and thrombosis of unspecified veins of right upper extremity
DVT/PE	I82702	Chronic embolism and thrombosis of unspecified veins of left upper extremity
DVT/PE	I82703	Chronic embolism and thrombosis of unspecified veins of upper extremity, bilateral
DVT/PE	I82709	Chronic embolism and thrombosis of unspecified veins of unspecified upper extremity
DVT/PE	I82711	Chronic embolism and thrombosis of superficial veins of right upper extremity
DVT/PE	I82712	Chronic embolism and thrombosis of superficial veins of left upper extremity
DVT/PE	I82713	Chronic embolism and thrombosis of superficial veins of upper extremity, bilateral
DVT/PE	I82719	Chronic embolism and thrombosis of superficial veins of unspecified upper extremity
DVT/PE	I82721	Chronic embolism and thrombosis of deep veins of right upper extremity
DVT/PE	I82722	Chronic embolism and thrombosis of deep veins of left upper extremity
DVT/PE	I82723	Chronic embolism and thrombosis of deep veins of upper extremity, bilateral
DVT/PE	I82729	Chronic embolism and thrombosis of deep veins of unspecified upper extremity
DVT/PE	I82811	Embolism and thrombosis of superficial veins of right lower extremity
DVT/PE	I82812	Embolism and thrombosis of superficial veins of left lower extremity
DVT/PE	I82813	Embolism and thrombosis of superficial veins of lower extremities, bilateral
DVT/PE	I82819	Embolism and thrombosis of superficial veins of unspecified lower extremity

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
DVT/PE	I82890	Acute embolism and thrombosis of other specified veins
DVT/PE	I82891	Chronic embolism and thrombosis of other specified veins
DVT/PE	I8290	Acute embolism and thrombosis of unspecified vein
DVT/PE	I8291	Chronic embolism and thrombosis of unspecified vein
DVT/PE	I82A11	Acute embolism and thrombosis of right axillary vein
DVT/PE	I82A12	Acute embolism and thrombosis of left axillary vein
DVT/PE	I82A13	Acute embolism and thrombosis of axillary vein, bilateral
DVT/PE	I82A19	Acute embolism and thrombosis of unspecified axillary vein
DVT/PE	I82A21	Chronic embolism and thrombosis of right axillary vein
DVT/PE	I82A22	Chronic embolism and thrombosis of left axillary vein
DVT/PE	I82A23	Chronic embolism and thrombosis of axillary vein, bilateral
DVT/PE	I82A29	Chronic embolism and thrombosis of unspecified axillary vein
DVT/PE	I82B11	Acute embolism and thrombosis of right subclavian vein
DVT/PE	I82B12	Acute embolism and thrombosis of left subclavian vein
DVT/PE	I82B13	Acute embolism and thrombosis of subclavian vein, bilateral
DVT/PE	I82B19	Acute embolism and thrombosis of unspecified subclavian vein
DVT/PE	I82B21	Chronic embolism and thrombosis of right subclavian vein
DVT/PE	I82B22	Chronic embolism and thrombosis of left subclavian vein
DVT/PE	I82B23	Chronic embolism and thrombosis of subclavian vein, bilateral
DVT/PE	I82B29	Chronic embolism and thrombosis of unspecified subclavian vein
DVT/PE	I82C11	Acute embolism and thrombosis of right internal jugular vein
DVT/PE	I82C12	Acute embolism and thrombosis of left internal jugular vein
DVT/PE	I82C13	Acute embolism and thrombosis of internal jugular vein, bilateral
DVT/PE	I82C19	Acute embolism and thrombosis of unspecified internal jugular vein
DVT/PE	I82C21	Chronic embolism and thrombosis of right internal jugular vein
DVT/PE	I82C22	Chronic embolism and thrombosis of left internal jugular vein
DVT/PE	I82C23	Chronic embolism and thrombosis of internal jugular vein, bilateral
DVT/PE	I82C29	Chronic embolism and thrombosis of unspecified internal jugular vein
DVT/PE	Z86718	Personal history of other venous thrombosis and embolism
Atrophic vaginitis	N905	Atrophy of vulva
Atrophic vaginitis	N952	Postmenopausal atrophic vaginitis
Hyperhidrosis	L74510	Primary focal hyperhidrosis, axilla
Hyperhidrosis	L74511	Primary focal hyperhidrosis, face
Hyperhidrosis	L74512	Primary focal hyperhidrosis, palms
Hyperhidrosis	L74513	Primary focal hyperhidrosis, soles
Hyperhidrosis	L74519	Primary focal hyperhidrosis, unspecified
Hyperhidrosis	L7452	Secondary focal hyperhidrosis
Hyperhidrosis	R61	Generalized hyperhidrosis
Obesity	Z6830	Body mass index [BMI] 30.0-30.9, adult
Obesity	Z6831	Body mass index [BMI] 31.0-31.9, adult

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Obesity	Z6832	Body mass index [BMI] 32.0-32.9, adult
Obesity	Z6833	Body mass index [BMI] 33.0-33.9, adult
Obesity	Z6834	Body mass index [BMI] 34.0-34.9, adult
Obesity	Z6835	Body mass index [BMI] 35.0-35.9, adult
Obesity	Z6836	Body mass index [BMI] 36.0-36.9, adult
Obesity	Z6837	Body mass index [BMI] 37.0-37.9, adult
Obesity	Z6838	Body mass index [BMI] 38.0-38.9, adult
Obesity	Z6839	Body mass index [BMI] 39.0-39.9, adult
Obesity	Z6841	Body mass index [BMI] 40.0-44.9, adult
Obesity	Z6842	Body mass index [BMI] 45.0-49.9, adult
Obesity	Z6843	Body mass index [BMI] 50.0-59.9, adult
Obesity	Z6844	Body mass index [BMI] 60.0-69.9, adult
Obesity	Z6845	Body mass index [BMI] 70 or greater, adult
Obesity	E6601	Morbid (severe) obesity due to excess calories
Obesity	E6609	Other obesity due to excess calories
Obesity	E662	Morbid (severe) obesity with alveolar hypoventilation
Obesity	E668	Other obesity
Obesity	E66811	Obesity, class 1
Obesity	E66812	Obesity, class 2
Obesity	E66813	Obesity, class 3
Obesity	E6689	Other obesity not elsewhere classified
Obesity	E669	Obesity, unspecified
Obesity	E8882	Obesity due to disruption of MC4R pathway
Metabolic syndrome	E8881	Metabolic syndrome
Metabolic syndrome	E88810	Metabolic syndrome
Metabolic syndrome	E88811	Insulin resistance syndrome, Type A
Metabolic syndrome	E88818	Other insulin resistance
Metabolic syndrome	E88819	Insulin resistance, unspecified
Hyperlipidemia	E782	Mixed hyperlipidemia
Hyperlipidemia	E784	Other hyperlipidemia
Hyperlipidemia	E7849	Other hyperlipidemia
Hyperlipidemia	E785	Hyperlipidemia, unspecified
Hypercholesterolemia	E780	Pure hypercholesterolemia
Hypercholesterolemia	E7800	Pure hypercholesterolemia, unspecified
Hypercholesterolemia	E7801	Familial hypercholesterolemia
Hypertension	I10	Essential (primary) hypertension
Hypertension	I151	Hypertension secondary to other renal disorders
Hypertension	I152	Hypertension secondary to endocrine disorders
Hypertension	I158	Other secondary hypertension
Hypertension	I159	Secondary hypertension, unspecified

COMORBIDITY	DIAGNOSIS CODE	DESCRIPTION
Hypertension	I1A0	Resistant hypertension
Hypertension	R030	Elevated blood-pressure reading, without diagnosis of hypertension
Hypertension	Z0131	Encounter for examination of blood pressure with abnormal findings

APPENDIX FIGURE C: MENOPAUSE DIAGNOSIS BY AGE COHORT

ALL MENOPAUSE				
AGE BAND	NON-DIAGNOSED MEMBERS	DIAGNOSED MEMBERS	TOTAL MEMBERS	PREVALENCE
40–44	361,195	40,465	401,660	10.1%
45–49	305,448	95,323	400,771	23.8%
50–54	295,298	153,566	448,864	34.2%
55–59	326,714	132,778	459,492	28.9%
60–64	263,830	93,723	357,553	26.2%
Overall	1,552,485	515,855	2,068,340	24.9%

APPENDIX FIGURE D: INCIDENT MENOPAUSE DIAGNOSIS BY AGE COHORT

INCIDENT MENOPAUSE (NO DIAGNOSIS SEEN IN 2022)				
AGE BAND	NON-DIAGNOSED MEMBERS	DIAGNOSED MEMBERS	TOTAL MEMBERS	PREVALENCE
40–44	371,074	30,586	401,660	7.6%
45–49	334,259	66,512	400,771	16.6%
50–54	359,327	89,537	448,864	19.9%
55–59	389,280	70,212	459,492	15.3%
60–64	304,851	52,702	357,553	14.7%
Overall	1,758,791	309,549	2,068,340	15.0%

Solutions for a world at risk™

Milliman leverages deep expertise, actuarial rigor, and advanced technology to develop solutions for a world at risk. We help clients in the public and private sectors navigate urgent, complex challenges—from extreme weather and market volatility to financial insecurity and rising health costs—so they can meet their business, financial, and social objectives. Our solutions encompass insurance, financial services, healthcare, life sciences, and employee benefits. Founded in 1947, Milliman is an independent firm with offices in major cities around the globe.

milliman.com

CONTACT

Melanie Kuester
Melanie.Kuester@milliman.com

Holly Zeitvogel
Holly.Zeitvogel@milliman.com

Emma Todd
Emma.Todd@milliman.com

© 2026 Milliman, Inc. All Rights Reserved. The materials in this document represent the opinion of the authors and are not representative of the views of Milliman, Inc. Milliman does not certify the information, nor does it guarantee the accuracy and completeness of such information. Use of such information is voluntary and should not be relied upon unless an independent review of its accuracy and completeness has been performed. Materials may not be reproduced without the express consent of Milliman.

ENDNOTES

1 Faubion, S.S., et al. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. Available from https://doi.org/10.1097/GME.0000000000002028.

2 Avis, N.E., Colvin, A., Bromberger, J.T., Hess, R., Matthews, K.A., Ory, M., & Schocken, M. (2009). Change in health-related quality of life over the menopausal transition in a multiethnic cohort of middle-aged women: Study of Women's Health Across the Nation. Menopause, 16(5), 860–869. Available from https://doi.org/10.1097/gme.0b013e3181a3cdaf.

3 Cagnacci, A., & Venier, M. (2019). The controversial history of hormone replacement therapy. Medicina, 55(9), 602. Available from https://doi.org/10.3390/medicina55090602.

4 U.S. Food & Drug Administration. (2025, November 10). FDA requests labeling changes related to safety information to clarify the benefit/risk considerations for menopausal hormone therapies. Retrieved September 2, 2026, from https://www.fda.gov/drugs/drug-alerts-and-statements/fda-requests-labeling-changes-related-safety-information-clarify-benefitrisk-considerations.

5 Allen, J.T., Laks, S., Zahler-Miller, C., Rungruang, B.J., Braun, K., Goldstein, S.R., & Schnatz, P.F. (2023). Needs assessment of menopause education in United States obstetrics and gynecology residency training programs. Menopause, 30(10), 1002–1005. Available from https://doi.org/10.1097/GME.0000000000002234.

6 Dominus, S. (2023, February 1). Women have been misled about menopause. The New York Times Magazine. Available from https://www.nytimes.com/2023/02/01/magazine/menopause-hot-flashes-hormone-therapy.html.

7 Berman, K. (2025, April 14). After decades of misunderstanding, menopause is finally having its moment. Yale School of Medicine. Retrieved September 2, 2026, from https://medicine.yale.edu/news-article/after-decades-of-misunderstanding-menopause-is-finally-having-its-moment.

8 Harker, J. (2024). President Biden requests $12B for research on women's health. The NIH Catalyst, 32(3). Retrieved September 2, 2026, from https://irp.nih.gov/catalyst/32/3/president-biden-requests-12b-for-research-on-womens-health.

9 Menopause Education Center. (2026, June 4). Menopause workplace mandates are becoming law. Is your organization ready? Available from https://menopauseclasses.com/menopause-legislation-report.

10 SWAN Publication List. (2025, February 10). Retrieved September 2, 2026, from https://www.swanstudy.org/wps/wp-content/uploads/2025/02/PUBLICATION_LIST-2025-02-10.pdf.

11 Gatenby, C., & Simpson P. (2024, January 18). Menopause: Physiology, definitions, and symptoms. Best Practice & Research Clinical Endocrinology & Metabolism, 38(1). Available from https://doi.org/10.1016/j.beem.2023.101855.

12 Ibid.

13 Delamater, L. & Santoro, N. (2018, September). Management of perimenopause. Clinical Obstetrics & Gynecology, 61(3), 419–432. Available from https://doi.org/10.1097/GRF.0000000000000389.

14 Santoro, N., & Randolph, J.F. (2011, September). Reproductive hormones and the menopause transition. Obstetrics and Gynecology Clinics of North America, 38(3), 455–466. Available from https://doi.org/10.1016/j.ogc.2011.05.004.

15 Freeman, E.W., Sammel, M.D., Lin, H., Gracia, C.R., Pien, G.W., Nelson, D.B., & Sheng, L. (2007, August). Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstetrics & Gynecology, 110(2), 230–240. Available from https://doi.org/10.1097/01.AOG.0000270153.59102.40.

16 Gibson, C.J., et al. (2025). Epidemiology and clinical outcomes of vasomotor symptoms among perimenopausal women and women aged 65 years or older in the U.S.: A systematic review. Women & Health, 64(9), 687–703. Retrieved September 2, 2026, from https://doi.org/10.1080/03630242.2024.2392136.

17 El Khoudary, S.R., et al. (2020, November 30). Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation, 142(25), e506–e532. Retrieved September 2, 2026, from https://doi.org/10.1161/CIR.0000000000000912.

18 Kapoor, E., et al. (2025, November). Addressing menopause symptoms: Barriers and opportunities for improvement. Mayo Clinic Proceedings, 100(11), 1897–1907. https://doi.org/10.1016/j.mayocp.2025.02.018.

19 Faubion, S.S., et al. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. Available from https://doi.org/10.1097/GME.0000000000002028.

20 Ibid.

21 Ibid.

22 Ibid.

23 Kapoor, E., et al. (2025, November). Addressing menopause symptoms: Barriers and opportunities for improvement. Mayo Clinic Proceedings, 100(11), 1897–1907. https://doi.org/10.1016/j.mayocp.2025.02.018.

24 Faubion, S.S., et al. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. Available from https://doi.org/10.1097/GME.0000000000002028.

25 U.S. Food & Drug Administration. (2025, November 10). HHS advances women's health, removes misleading FDA warnings on hormone replacement therapy. Retrieved September 2, 2026, from https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy.

26 Yanachkova, V., Vasileva-Slaveva, M., Kostov, S., & Yordanov, A. (2025, October 10). Reconsidering hormone replacement therapy: Current insights on utilisation in premenopausal and menopausal women: An overview. Journal of Clinical Medicine, 14(20), 7156. Retrieved September 2, 2026, from https://doi.org/10.3390/jcm14207156.

27 Keye, C., Murphy, M., Saab, M.M., & O'Driscoll, M. (2025, November 14). Menopause education of healthcare professionals: A scoping review protocol. PLoS One, 20(11). Retrieved September 2, 2026, from https://doi.org/10.1371/journal.pone.0325012.

28 Cumming, G.P., Herald, J., Moncur, R., Currie, H., & Lee, A.J. (2007, June 1). Women's attitudes to hormone replacement therapy, alternative therapy, and sexual health: A web-based survey. Menopause International, 13(2), 79–83. Available from https://doi.org/10.1258/175404507780796424.

29 DePree, B., Houghton, K., Shiozawa, A., Esterberg, E., King, D.D., Kim, J., & Mancuso, S. (2023, January). Treatment and resource utilization for menopausal symptoms in the United States: A retrospective review of real-world evidence from U.S. electronic health records. Menopause, 30(1), 70–79. Retrieved September 2, 2026, from https://doi.org/10.1097/GME.0000000000002095.

30 El Khoudary, S.R., et al. (2020, November 30). Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation, 142(25), e506–e532. Retrieved September 2, 2026, from https://doi.org/10.1161/CIR.0000000000000912.

31 Avis, N.E., Colvin, A., Bromberger, J.T., Hess, R., Matthews, K.A., Ory, M., & Schocken, M. (2009). Change in health-related quality of life over the menopausal transition in a multiethnic cohort of middle-aged women: Study of Women's Health Across the Nation. Menopause, 16(5), 860–869. Available from https://doi.org/10.1097/gme.0b013e3181a3cdaf.

32 Shufelt, C.L., et al. (2023, June). The 2023 hormone therapy position statement of The North American Menopause Society. Menopause, 30(6), 573–590. Available from https://doi.org/10.1097/GME.0000000000002200.

33 Mervosh, N., & Devi, G. (2025, June 29). Estrogen, menopause, and Alzheimer's disease: Understanding the link to cognitive decline in women. Frontiers in Molecular Biosciences, 12. Retrieved September 2, 2026, from https://doi.org/10.3389/fmolb.2025.1634302.

34 Mosconi, L., Nerattini, M., Williams, S., & Fink, M. (2025, January 16). New horizons in menopause, menopausal hormone therapy, and Alzheimer's disease: Current insights and future directions. Journal of Clinical Endocrinology & Metabolism, 110(4), 911–921. Retrieved September 2, 2026, from https://doi.org/10.1210/clinem/dgaf026.

35 El Khoudary, S.R., et al. (2020, November 30). Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation, 142(25), e506–e532. Retrieved September 2, 2026, from https://doi.org/10.1161/CIR.0000000000000912.

36 Iyer, T.K. & Hirsch, H. (2022, January). Clinical impact of 2020 American Heart Association statement on menopause and cardiovascular disease risk. Cleveland Clinic Journal of Medicine, 89(1), 13–17. Retrieved September 2, 2026, from https://doi.org/10.3949/ccjm.89a.21031.

37 Carlson, K., & Vadakekut, E.S. (2026, March 23). Menopause. StatPearls. Retrieved September 2, 2026, from https://www.ncbi.nlm.nih.gov/books/NBK507826.

38 Barrington, A., Bell, D., Sun, M., Prakash, S., & Yih, S. (2023, June). Healthcare cost and utilization for women in menopause. Milliman. Retrieved September 2, 2026, from https://media.milliman.com/v1/media/edge/images/millimaninc5660-milliman6442-prod27d5-0001/media/Milliman/PDFs/2023-Articles/6-27-23_Healthcare-Cost-and-Utilization-for-Women-in-Menopause.pdf.

39 Harlow, S.D., Burnett-Bowie, S.-A.M., Greendale, G.A., Avis, N.E., Reeves, A.N., Richards, T.R., & Lewis, T.T. (2022, February 8). Disparities in reproductive aging and midlife health between black and white women: The Study of Women's Health Across the Nation (SWAN). Women's Midlife Health, 8. Retrieved September 2, 2026, from https://doi.org/10.1186/s40695-022-00073-y.

40 El Khoudary, S.R., et al. (2020, November 30). Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation, 142(25), e506–e532. Retrieved September 2, 2026, from https://doi.org/10.1161/CIR.0000000000000912.